http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2739125-C1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f1113fd86ed96e76d7b1792ce8e219fc
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K8-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-16
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K8-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-16
filingDate 2020-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2020-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b443d29b8bd48f1cbed8e31cd024da38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1fc03d954554b40796c13070fa3ee1ec
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f64246b3b187bf37dd5f6ab31d65a545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9bdfd2339940feffdc6ed004eceb5276
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_193244215fa44955046e5edd628e4054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac89a675a3e87de9b3fec9f698d0e293
publicationDate 2020-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber RU-2739125-C1
titleOfInvention Method of treating nephrotransplant lymphocele after allogenic renal transplantation
abstract FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to nephrology, and can be used in treating graft lymphocele after allogenic renal transplantation. Method comprises external drainage under ultrasound guidance with installation of a plastic catheter into the lymphocele cavity from the anterolateral side of the abdomen, aspiration of the contents and performing bacteriological analysis, if the test is negative, the content of total protein, creatinine and urea is evaluated if the derived values correspond to those in plasma of venous blood, then introduced into the lymphocele cavity by the installed catheter first sterilized 0.7–0.9 % solution of allogenic collagen type 1, then autologous thrombocyte-rich plasma (TRP) in ratio of 3 to 1, wherein total volume of administered preparations - allogenic collagen solution and TRP, is determined based on the volume of the lymphatic well cavity, but not more than 12 ml, then the drainage is shut off for 1 hour, after the opening of the drainage, the lymphocele cavity is aspirated, after which the drainage is switched to the self-drain with the pressure bandage application, introduction of allogenic type 1 collagen and autologous thrombocyte-rich plasma is repeated up to three sessions with an interval between administrations of 2–4 days, a day after each introduction, the volume of draining fluid is estimated, when fluid volume is 25 ml or less per day, ultrasonic control of lymphocele cavity is performed, and in case of absence of fluid accumulation in lymphocele cavity treatment is completed, in case if after third introduction volume of leakage fluid is more than 25 ml per day, wherein the volume of the flowing fluid is reduced compared to the volume measured after the first administration, the second stage of treatment is performed by introducing sterilized 0.7–0.9 % solution of type 1 allogenic collagen to three sessions in the volume, similar to volume of introduction of this preparation at the first stage, with interval between administrations of 2–4 days.EFFECT: use of the invention enables the effective treatment of the patients after kidney transplantation complicated by the lymphocele formation in the post-transplantation period ensured by stimulating the regeneration process without tissue damage.1 cl, 1 ex
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2797741-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2804229-C2
priorityDate 2020-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011008302-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2177264-C2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID410087
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419551813
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID3565880
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID4363005
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID454031468
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419588607
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2713
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5281078
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID33727
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCO01945
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1176
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419590725
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID3565413
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54684461
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419483880
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID173839
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID137319715
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448241444

Total number of triples: 45.